Crossmark

GNE myopathy: from clinics and genetics to pathology and research strategies

Crossref DOI link: https://doi.org/10.1186/s13023-018-0802-x

Published Online: 2018-05-02

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pogoryelova, Oksana

González Coraspe, José Andrés

Nikolenko, Nikoletta

Lochmüller, Hanns

Roos, Andreas
Funding

Funding for this research was provided by:

Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen

European Union Seventh Framework Programme (305444 (RD-Connect), 305121 (NeurOmics))

Deutsche Gesellschaft für Muskelkranke
License Information

Text and Data Mining valid from 2018-05-02
More Information

Article History

Received: 27 December 2017

Accepted: 9 April 2018

First Online: 2 May 2018

Ethics approval and consent to participate

: Not applicable.

: The authors have consent to use the image shown in Fig..

: The authors declare that they do not have any competing interests.OP and HL have served as investigators on clinical trials and and a Disease Monitoring Programme for GNE myopathy carried out by Newcastle University and the Newcastle NHS Trust sponsored by Ultragenyx Pharmaceuticals (NCT01784679, NCT02377921, NCT02736188).

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.